senior notes offering

The company plans to use the net proceeds to partially fund the $7.2 billion acquisition of pharmaceutical contract development and manufacturing firm Patheon.

The firm's European subsidiary is offering the new senior notes to repay, in part, all outstanding aggregate principal amounts on senior notes due later this month.

The company said it will use the net proceeds to redeem the outstanding $500 million aggregate principal amount of senior notes maturing in January 2018.

The ratings agency also assigned a Negative Rating Watch to the firm's notes offering, noting it will resolve this notation as more details of the offering become available.

The firm plans to use the funds to repay outstanding debts and for general corporate purposes.

The firm has not disclosed the amount it is seeking, but said it plans to use the funds to repay outstanding debts and for general corporate purposes.

The company said it will use most of the proceeds to redeem the outstanding $900 million principal amount of its 1.30 percent senior notes due 2017.

Fitch has given the two-year senior notes offering a BBB rating with a Stable outlook. 

The 10-year notes were rated BBB by Fitch, which also declared the ratings outlook Stable.

The firm sold three series of senior notes and will use proceeds to repay other outstanding debt.

Pages

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.